Progress in second-line antibody therapies for advanced esophageal squamous cell carcinoma.

Nozomu OguraShun YamamotoKen Kato

Published in: Expert opinion on biological therapy (2024)

The standard first-line treatments for patients with advanced ESCC contain ICIs. Therefore, drugs with different mechanisms of action that can overcome resistance to ICIs are needed as second-line or later-line treatments to improve clinical outcomes in these patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
peritoneal dialysis
patient reported outcomes
drug induced